Daily non-political popular news in brief.
Shrinkage of prostate led to overestimation of cancer risk in trial
09-12-2007 · EurekAlert!Reanalysis of data from the Prostate Cancer Prevention Trial of a chemopreventive agent for prostate cancer shows that the excess prevalence of high-grade prostate cancer in the drug-treated group may be attributable to shrinkage of the prostate at the time of biopsy.
Read more »
Keywords: shrinkage, prostate, led, overestimation, cancer, risk, trial
« Previous | Next »
Similar news on "Shrinkage of prostate led to overestimation of cancer risk in trial":
- Herceptin does not increase heart failure in patients long-term
06-03-2007 · EurekAlert!
Risk of congestive heart failure in women treated with trastuzumab and combination chemotherapy for early-stage breast cancer did not increase over time according to a five-year follow-up of National Surgical Adjuvant Breast and Bowel Project trial B-31 led by the University of Pittsburgh School of Medicine. Based on the findings, the research team developed a prediction model to help oncologists assess the risk of heart failure in individual breast cancer patients prior to treatment with Herceptin and chemotherapy.
Similar news · Read more »
- Henry Ford Hospital expands research on gene and radiation therapy for prostate cancer
02-06-2008 · EurekAlert!
Henry Ford Hospital is embarking on an expanded major clinical trial involving the use of gene therapy in combination with radiation therapy, to determine if the combined treatment is more effective than radiation therapy alone for patients with intermediate risk prostate cancer.The clinical trial is part of a $9 million grant from the National Cancer Institute awarded to Henry Ford to study the effectiveness of gene therapy to treat prostate cancer.
Similar news · Read more »
- Study identifies a common genetic risk factor for colorectal and prostate cancer
07-08-2007 · EurekAlert!
A study led by researchers at the Keck School of Medicine of the University of Southern California has found that one of seven genetic risk factors previously identified as increasing the probability of developing prostate cancer also increases the probability of developing colorectal cancer.
Similar news · Read more »
- Anxiety linked to newly diagnosed DCIS patients' overestimation of breast cancer risks
02-12-2008 · EurekAlert!
Elevated levels of anxiety may cause women with ductal carcinoma in situ, the most common form of non-invasive breast cancer, to overestimate their risk of recurrence or dying from breast cancer, suggests a study led by researchers at Dana-Farber Cancer Institute in Boston.
Similar news · Read more »
- Herceptin does not increase heart failure in patients long term
06-03-2007 · EurekAlert!
Risk of congestive heart failure in women treated with trastuzumab and combination chemotherapy for early stage breast cancer did not increase over time according to a five-year follow up of National Surgical Adjuvant Breast and Bowel Project trial B-31 led by the University of Pittsburgh School of Medicine. Based on the findings, the research team developed a prediction model to help oncologists assess the risk of heart failure in individual breast cancer patients prior to treatment with Herceptin and chemotherapy.
Similar news · Read more »
- Study identifies multiple genetic risk factors for prostate cancer
04-01-2007 · EurekAlert!
A study led by researchers at the Keck School of Medicine of the University of Southern California and Harvard Medical School has identified seven genetic risk factors that predict risk for prostate cancer. According to the study's findings, these risk factors are clustered in a single region of the human genome on chromosome 8 and powerfully predict a man's probability of developing prostate cancer.
Similar news · Read more »
- Mass. General leading international trial of novel breast cancer drug
12-13-2006 · EurekAlert!
A clinical trial of a new targeted breast cancer drug, led by physicians at Massachusetts General Hospital Cancer Center, has begun enrolling patients. The TEACH (Tykerb Evaluation After CHemotherapy) trial will investigate the experimental drug Tykerb (lapatinib) in patients with early-stage, HER2-positive breast cancer who have not been treated with Herceptin, another targeted drug used for the same type of tumor.
Similar news · Read more »
- Novel regulation of the common tumor suppressor PTEN
01-11-2007 · EurekAlert!
PTEN is one of the most commonly mutated tumor suppressor genes. It is an antagonist for many cellular growth, proliferation and survival processes. When mutated or deleted, it causes cancers of the prostate, breast, colon and brain. Researchers led by scientists at Memorial Sloan-Kettering Cancer Center have now identified fundamentally novel regulatory mechanisms of PTEN function. The findings from two related studies are published in the Jan. 12 issue of Cell.
Similar news · Read more »
- PSA doubling predicts prostate cancer recurrence
04-09-2007 · EurekAlert!
A detectable level of prostate-specific antigen (PSA) is the first indicator of recurrent prostate cancer after radical prostatectomy. In a new Mayo Clinic study, the concept of PSA doubling time is found to be a reliable tool to distinguish which patients have prolonged innocuous PSA levels after therapy from those who are at great risk for disease recurrence and death from prostate cancer. Doubling time is defined as the duration for PSA levels in the blood to increase by 100 percent.
Similar news · Read more »
- Phase II study shows HRPC patients with bone metastases see improved survival with ZD4054
09-25-2007 · EurekAlert!
New Phase II data presented today suggest that ZD4054, a novel compound in development for the treatment of men with hormone-resistant prostate cancer, could offer a promising improvement in overall survival in men with metastatic HRPC who were asymptomatic or mildly symptomatic for pain.1 Patients who received ZD4054 10mg once-daily experienced a 45 percent reduction in the risk of death compared to placebo.
Similar news · Read more »
